FDA Drug recall D-1606-2020
WP Thyroid, Westhroid Pure, Thyroid USP, [liothyronine (T3) 2.25 mcg and levothyroxine (T4) 9.5 mcg], 1/4 Grain (16.25 mg) Tablets, package…
- FDA Drug
- Class II
- terminated
- Published 2020-09-23
On 2020-09-23 the FDA classified a Class II recall of WP Thyroid, Westhroid Pure, Thyroid USP, [liothyronine (T3) 2.25 mcg and levothyroxine (T4) 9.5 mcg], 1/4 Grain (16.25 mg) Tablets, package… by Rlc Labs, citing CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1606-2020 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2020-08-25 |
| Published | 2020-09-23 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Rlc Labs |
| Distribution | US |
Product
WP Thyroid, Westhroid Pure, Thyroid USP, [liothyronine (T3) 2.25 mcg and levothyroxine (T4) 9.5 mcg], 1/4 Grain (16.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-5450-4; b) 60-count bottles, NDC 64727-5450-5; c) 90-count bottles, NDC 64727-5450-6; d) 100-count bottles, NDC 64727-5450-1; and e) 1,000-count bottles, NDC 64727-5450-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.
Reason
CGMP Deviations: manufactured under the same conditions as those found to be subpotent.
Identifiers
| code_info | All lots with expiry between 10/2020-07/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1606-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.